parallel randomized trial

S003002

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Antipsychotic associated weight gain and severe mental illnessS003002

Design

Randomized: 31
Start year
Treatment: 36 weeks
Countries: Australia (6 sites)
Sponsor: (not reported)
Eligibility: age 18 or older; schizophrenia or schizoaffective on clozapine 18 weeks or more; BMI 26 or more

Conduct and analysis

Blinding: double blind
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Semaglutide 2.0 mg subcutaneous once weekly Semaglutide titrated to 2.0 mg weekly	clozapine; lifestyle: not reported	15
A2	Placebo Placebo	clozapine; lifestyle: not reported	16

Analyses this trial contributes to

Results

3 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Percent body weight change (short trials) (3 lines; O10B)

Week	Arm	Statistic	Estimate	SE or SD	Detail
36	A1	percent change	-13.88 percent	0.90	not stated; other; R0012753:Abstract
36	A1 vs A2	md	-13.46 percent		not stated; other; R0012753:Abstract
36	A2	percent change	-0.42 percent	0.93	not stated; other; R0012753:Abstract